InterVenn is focusing on the development and commercialization of its Advanced Adenoma and Colorectal Cancer screening platform to change the paradigm for the detection of early-stage disease
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–InterVenn Biosciences, a clinical technology company leveraging glycoproteomics to transform the future of healthcare, today announced that Erwin Estigarribia has been appointed President and Chief Operating Officer, effective immediately. Prior to his appointment, Estigarribia was InterVenn’s Chief Operating Officer, where he was instrumental in leading the company’s lab operations and product development efforts. InterVenn has a CLIA/CAP-certified lab in San Francisco where the company is developing assays to detect and understand cancer and diseases of the immune system. In his new role as President, Estigarribia will continue to oversee laboratory operations and product development while assuming responsibility for commercial operations and payer engagement.
Over the past fifteen months, InterVenn has made considerable progress on the development of several assays across oncology and immunology. Upon review of the latest information related to InterVenn’s Advanced Adenoma (AA) and Colorectal Cancer (CRC) efforts, the company has decided to reprioritize investment to accelerate the development and commercialization of the AA and CRC franchise. It is expected that enrollment in the 3,000-patient prospective Noninvasive Identification of CRC and Adenomas in Early Stages (NICE, NCT05445570) study will be completed by year end, with final results available in the first half of 2023.
“Erwin Estigarribia is a talented leader who has been instrumental in InterVenn’s success over the last few years. His expanded leadership role will accelerate value creation of the AA and CRC franchise at InterVenn,” said Aldo Carrascoso, Co-Founder and CEO of InterVenn Biosciences. “Further validation and commercialization of InterVenn’s glycoproteomic-based platform will help transform the detection of early-stage disease and change the way the medical community approaches the detection and understanding of disease.”
“I am honored to step into this new role at InterVenn as we will continue the development of solutions that have the potential to impact how clinicians identify and understand disease. InterVenn is successfully executing a strategy that will reduce the rate of deaths from cancer and other life-threatening conditions by detecting disease at earlier stages than is conventionally possible today,” said Estigarribia. “As we transition to being a commercial company, I am excited to lead the efforts to engage with payers and oversee the product strategy of our AA and CRC platform for early detection of cancer and adenomas.”
Estigarribia was recently named one of the Top 25 Health Tech COOs, as reported by Becker’s Hospital Review. Before joining InterVenn, Estigarribia held executive-level positions at global life sciences companies, including Chiron, Novartis, Geron, Nugen, CardioDX, and Applied Proteomics. He graduated with a bachelor’s degree in chemical and bioprocessing engineering (with honors) from Swinburne University of Technology, Melbourne Australia.
NICE Study: Non-Invasive Identification of Colorectal Cancer and Adenomas in Early Stages
In May 2022, InterVenn started enrolling 3,000 patients in a prospective study to train and validate a blood-based, glycoproteomic test for the early detection of AA and CRC. The study, known as Noninvasive Identification of Colorectal Cancer and Adenomas in Early Stages (the NICE Study), is intended to validate InterVenn’s platform to detect early CRC and precancerous adenomas by collecting blood samples and associated relevant clinical information from average-risk participants undergoing routine screening colonoscopy as well as participants undergoing colonoscopy for surveillance or diagnostic indication. Following completion of the NICE study, InterVenn intends to introduce a product that could significantly improve diagnosis and treatment of cancer.
Early detection of CRC remains a huge unmet need, despite years of effort to find solutions. Colorectal cancer is the second leading cause of cancer-related death in the US, but about a third of adults aged 50-75 are not up to date with CRC screening, and more than 44 million people who are eligible for CRC screening have not yet been screened, according to the Centers for Disease Control and Prevention (CDC).
About InterVenn Biosciences
InterVenn is a clinical technology company unlocking the value of glycoproteomics for the development of transformational healthcare solutions. The glycoproteome is a source of life-critical information about human biology that has the potential to significantly improve patient outcomes, but it has remained inaccessible due to its vast complexity. InterVenn is pioneering a new AI-powered platform to decode the potential of the glycoproteome at clinically meaningful scale for the first time in history. The company has developed a platform capable of producing a robust pipeline of powerful clinical applications, ranging from early disease screening to diagnostics and potentially therapeutics. Founded by Nobel Laureate Dr. Carolyn Bertozzi, world-class scientist and distinguished professor Dr. Carlito Lebrilla and leading AI/ML expert Aldo Carrascoso, InterVenn will contribute to making the new era of personalized, predictive, and preventative care a reality. For more information about InterVenn, visit www.intervenn.com.
Vice President, Corporate Communications
David Deuchler, CFA